Prelude Therapeutics (PRLD) Assets Average (2020 - 2026)

Prelude Therapeutics has disclosed Assets Average across 7 years of filings, most recently posting $130.5 million for Q1 2026.

• Assets Average for Q1 2026 came in at $130.5 million, down 17.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.5 million (down 17.62% YoY), and the FY2025 annual result was $158.4 million, down 30.09% from the prior year.
• Assets Average came in at $130.5 million for Q1 2026 at Prelude Therapeutics, up from $118.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $292.9 million in Q1 2022 to a low of $104.8 million in Q3 2025.
• The 5-year median for Assets Average is $231.4 million (2022), against an average of $209.8 million.
• Across the five-year window, Assets Average advanced 25.3% in 2024 and tumbled 50.26% in 2025, its largest moves.
• Prelude Therapeutics' Assets Average stood at $231.4 million in 2022, then grew by 15.85% to $268.1 million in 2023, then tumbled by 30.48% to $186.4 million in 2024, then slumped by 36.67% to $118.0 million in 2025, then advanced by 10.54% to $130.5 million in 2026.
• The last three Assets Average figures came in at $130.5 million (Q1 2026), $118.0 million (Q4 2025), and $104.8 million (Q3 2025), per Business Quant data.